<qa>  What is the most active regimen in patients with advanced melanoma?Effective adjuvant treatment can increase cure in patients with high-risk resected melanoma. High dose interferon is a standard of care in the adjuvant setting but is highly toxic and marginally effective. The combination of ipilimumab and nivolumab is the most active regimen in patients with advanced melanoma so there is clear rationale to test this regimen in the adjuvant setting. Investigators are testing if nivolumab 3mgkg every 2 weeks with 1mgkg ipilimumab every 6 weeks in the high risk adjuvant setting. The duration of therapy will be six months. 